Radiopharm Theranostics represents a promising investment opportunity in the rapidly growing field of radiopharmaceuticals, leveraging its innovative technology platform and diverse clinical pipeline.
Radiopharm Theranostics (ASX:RAD) is an innovative biopharmaceutical company specializing in the development of radiopharmaceutical products for both diagnostic and therapeutic applications. Founded with a mission to address significant unmet medical needs, particularly in oncology, the company has positioned itself at the forefront of the rapidly evolving field of precision medicine.
Radiopharm Theranostics presents a compelling value proposition for investors, characterized by several key factors:
Lantheus’ investment in Radiopharm marks a pivotal moment for both companies and holds substantial implications for the field of theranostics. The funding will facilitate Radiopharm's research and development efforts, accelerating its product pipeline and market presence. Under the agreement, Radiopharm will transfer two early preclinical assets to Lantheus for a further AU$3 million, fostering a collaborative relationship focused on radiopharmaceutical development. The collaboration positions Radiopharm to capitalize on the increasing demand for theranostic solutions, aligning with trends in personalized medicine. Moreover, this financial backing will support clinical trials and operational needs, while also aiming for the commercialization of their products.
Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
Radiopharm’s clinical stage development in the pipeline include:
The company recently received FDA approval for its investigational new drug application for 18-Pivalate (RAD 101). Labelled with the radioisotope F18, Pivalate is a small molecule that targets fatty acids synthase, which is overexpressed in brain tumours but not in normal cells.
Positive data from the company’s Phase 2 imaging trial of 17 patients with brain metastases has shown significant tumour uptake. Radiopharm holds an exclusive global license for the Pivalate platform.
Radiopharm highlights that Pivalate is potentially a new target for radiopharmaceutical brain imaging agents, and its unique mechanism of action may offer eligible patients a better option in relation to current imaging technology, which has many limitations.
Paul Hopper is the founder of Radiopharm Theranostics. He has over 25 years of experience in the biotech, healthcare and life sciences. Focused on start-up and rapid-growth companies, he has served as the founder, chairman, non-executive director or CEO of more than 15 companies in the US, Australia and Asia. Previous and current boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics and Polynoma. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk management, and strategy.
Riccardo Canevari has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals. He was most recently chief commercial officer of Novartis Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies, globally. He was responsible for global commercial strategy and country organizations in ~20 countries across North America, Europe and Asia. He was responsible for Lutathera’s in-market growth strategy and execution to build a blockbuster asset and for the pre-launch plan for Lu-PSMA 617 in metastatic prostate cancer. Prior to this, Canevari was senior vice-president and global head, breast cancer franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products, including KISQALI and PIQRAY. He also held various management roles with Novartis Pharma and Ethicon/Johnson & Johnson.
Dr. Sherin Al-Safadi is an accomplished industry leader with many years of experience in pharmaceuticals and biotech. Most recently she was vice-president – medical affairs at POINT Biopharma, where she led the strategic and tactical planning for Phase III support and launch preparation of radiopharmaceuticals. She also provided strategic input and leadership for business development and licensing opportunities. She currently serves as co-founder and president at Foundation Amal (Canada-USA), overseeing an executive leadership team of 12 directors and members, who led the successful 2021 cross-border expansion into the USA and spearheaded the development of a successful branding and communication strategy. Al-Safadi holds a PhD in neurobiology from Concordia University, an MBA in entrepreneurship & management from the John Molson School of Business, and a MSc in pharmacology (oncology drug development) from McGill University.
Vimal Patel joins RAD from Orum Therapeutics where he was vice-president, head of CMC and supply chain. He was responsible for all CMC functions including process and analytical development, manufacturing, quality control, quality assurance, regulatory and supply chain. He led the successful manufacture of two ADCs and contributed to filing an IND leading to a Phase-I trial. Prior to Orum, Patel held roles of increasing responsibility in process development and manufacturing sciences at several companies, including Actinium Pharmaceuticals. Patel also held a position at Pfizer where he contributed to the refiling of Mylotarg and the filing of Besponsa BLAs. He also developed manufacturing processes for various ADCs. He also held roles at Daiichi Sankyo, Progenics Pharmaceuticals and SibTech in various capacities. Patel has MS in biotechnology from University of Connecticut and B.S. in chemical engineering from Sardar Patel University.
Noel Donnelly brings more than 25 years of leadership experience in finance, strategy and operations within the biopharmaceutical and biotechnology industries. He has a distinguished track record of building and leading cross-functional teams, driving corporate governance and executing complex financial strategies that support rapid company. growth. Donnelly is current the chief financial officer of PepGen, where he oversaw the company's financial strategy through its successful IPO, raising U$120 million and leading subsequent financial efforts that secured an additional US$90 million. Donnelly was previously the CFO of EIP Pharma (now, CervoMed), where he led the company's IPO plannig phase. He had a 15-year tenure at Takeda/Shire PLC, in various senior roles, where he led critical R&D integrations and oversaw more than US$160 billion in integration planning and execution. He was instrumental in shaping the company's portfolio management strategy.
Developing innovative radiopharmaceuticals for a highly underserved oncology sector
Following the release of Cizzle Brands' second fiscal quarter 2025 financial results, the Company's management team will be hosting a webcast to provide further insight regarding the results in the context of the Company's ongoing business activities.
Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the "Company" or "Cizzle Brands") , today announced its plans to release financial results for the second quarter of its fiscal 2025 year ended January 31, 2025 (" FQ2 2025 ") after market close on Monday, March 17, 2025. These results will be available on Cizzle Brands' profile on SEDAR+ ( http://www.sedarplus.ca/ ).
Cizzle Brands will conduct a webcast to discuss these results on the Thursday of the following week. Information regarding the webcast is provided below:
The webcast's registration link may not be visible through some news aggregation services. Please refer to the News section of the Cizzle Brands' website for a version of this press release with the link. Alternatively, the link may be obtained by contacting Cizzle Brands' Investor Relations team.
Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "As a public company with our common shares traded in three different markets, we take pride in being transparent and communicative with our growing investor base. To that end, we are pleased to be hosting this webcast following the publication of our FQ2 2025 financial results, where we will be able to provide key, plain-language insights with respect to what is behind the numbers, and how they fit into our current operations as we continue to commercialize our brands CWENCH Hydration™ and Spoken Nutrition. Our management team is excited to deliver this presentation, and we encourage all current and prospective investors in Cizzle Brands to register to attend."
About Cizzle Brands Corporation
Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,200 stores in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.
For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/
For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com
For more information about the CWENCH All Canadian Games, please visit: https://www.cwenchallcanadian.com
Notice Regarding Images and Links: This press release may contain images and/or links to outside web pages, which could play an important role in providing the full context of the news update being conveyed through this press release. Some news aggregation services may remove these images and/or links at their discretion. Therefore, readers are encouraged to access SEDAR+ or the News section of the Cizzle Brands Corporation website to view this press release containing all images and/or links as originally published.
On behalf of the Board of Directors of the Company,
"John Celenza"
John Celenza, Founder, Chairman, and Chief Executive Officer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.
Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.
Footnotes
1 72% sequential growth of CWENCH Hydration™ 10-count units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 11,943 units to 20,543 units each quarter with this account
2 64% sequential growth of CWENCH Hydration™ 315-gram units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 2,730 units to 4,478 units each quarter with this account
3 39% sequential growth of CWENCH Hydration™ RTD beverage units sold during the calendar month of September 2024 compared to the calendar month of January 2025 with this account reflects unit sales increasing from 11,695 units per month to 16,280 units per month
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313759799/en/
For further information, please contact:
Setti Coscarella
Head of Corporate Development
investors@cizzlebrands.com
1-844-588-2088
News Provided by Business Wire via QuoteMedia
Among North American key accounts for the Company, retailers and distributors have been placing re-orders for CWENCH Hydration™, on average, once per week throughout the first half of this fiscal year. This recurring pace of re-orders clearly demonstrates strong distribution and a high velocity of in-store sales.
Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the "Company" or "Cizzle Brands") , is pleased to provide investors with an update on sales traction for its flagship product, CWENCH Hydration™ . Since the start of the Company's fiscal year (August 1, 2024), CWENCH Hydration™ has outperformed initial expectations as the brand continues to be commercialized across Canada and the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306779889/en/
CWENCH Hydration™ continues its strong performance across North America in 2025 (Photo: Business Wire)
To date, every retailer that is carrying CWENCH Hydration has placed at least one re-order within two months of carrying the product. Among four of the Company's key North American accounts, re-orders are being submitted, on average, once per week, with 111 cumulative wholesale orders from these four key accounts since August 1, 2024.
Cizzle Brands' President and Chief Revenue Officer Tucker Wright commented, "As we strategically introduce CWENCH Hydration™ to the market with key retail partners and cultivate a sustained sales pipeline through these channels, we can attribute this re-order rate to several factors. Foremost is the quality of the product, which we believe speaks for itself as customers come back to the store to buy more CWENCH after purchasing it for the first time. This is part of a broader trend, in which there is growing demand for premium healthy hydration options for athletes of all ages… and CWENCH's key differentiators – all-natural, low-sugar, non-plastic packaging – is helping it to excel in the category. Additionally, robust distribution logistics and prominent in-store marketing ( e.g. , endcap displays and point-of-sale materials) have helped to solidify an efficient operations cycle from the point of manufacture to the point of consumption. We will continue to scale the footprint of CWENCH Hydration™ using this playbook, and we are very pleased with the results achieved to date in this fiscal year."
In the Company's largest account in Canada (a national sporting goods retailer with over 100 locations), unit sales of the two Hydration Mix versions of CWENCH Hydration™ have grown by 72% 1 (10-Count) and 64% 2 (315-gram) sequentially from the first quarter of the present fiscal year (three-month period from August 1 2024 to October 31, 2024) to the second quarter of the present fiscal year (three-month period from November 1 2024 to January 31, 2025).
Similarly, unit sales of all four Ready-to-Drink ("RTD") flavours of CWENCH Hydration™ at Cizzle Brands' largest U.S. account (an upscale chain of fitness centres with over 100 locations throughout the United States) grew by 39% 3 from September of 2024 through January of 2025.
Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "Having launched CWENCH Hydration™ in May of 2024, the product has proven itself remarkably well in the Canadian and U.S. marketplaces, which has been sustaining our brand growth and product re-order rate while maintaining strong margins. As a healthy hydration option for athletes of all ages, the visibility of the CWENCH Hydration™ brand at the grassroots level has been instrumental to our growth. With orders coming in from athletes and trainers across professional sports teams and Division 1 colleges along with our support of 500 youth hockey teams representing over 12,000 youth hockey players across North America, these factors have helped to establish a substantial presence for CWENCH in the world of sports. Adults, teens, and children are asking for CWENCH by name and are making it part of their hydration playbook. We are only getting started with building market share for CWENCH Hydration™, and I believe that these early-stage reorder rates provide us with a growing confidence in terms of what is on the horizon for CWENCH and Cizzle Brands."
About Cizzle Brands Corporation
Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,200 stores in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.
For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/
For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com
Notice Regarding Images and Links: This press release may contain images and/or links to outside web pages, which could play an important role in providing the full context of the news update being conveyed through this press release. Some news aggregation services may remove these images and/or links at their discretion. Therefore, readers are encouraged to access SEDAR+ or the News section of the Cizzle Brands Corporation website to view this press release containing all images and/or links as originally published.
On behalf of the Board of Directors of the Company,
"John Celenza"
John Celenza, Founder, Chairman, and Chief Executive Officer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.
Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.
Footnotes
1 72% sequential growth of CWENCH Hydration™ 10-count units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 11,943 units to 20,543 units each quarter with this account
2 64% sequential growth of CWENCH Hydration™ 315-gram units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 2,730 units to 4,478 units each quarter with this account
3 39% sequential growth of CWENCH Hydration™ RTD beverage units sold during the calendar month of September 2024 compared to the calendar month of January 2025 with this account reflects unit sales increasing from 11,695 units per month to 16,280 units per month
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306779889/en/
For further information, please contact:
Setti Coscarella
Head of Corporate Development
investors@cizzlebrands.com
1-844-588-2088
News Provided by Business Wire via QuoteMedia
Pro Hockey Life is the world's largest hockey-centric retailer, with a unique "hockey megastore" concept that has been proudly serving Canadians since 1973. This past Saturday, CWENCH Hydration™ brand ambassador Coach Chippy held a meet-and-greet event at Pro Hockey Life's Vaughan Mills location to commemorate CWENCH Hydration's launch at the retailer.
Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the "Company" or "Cizzle Brands") , is pleased to announce that CWENCH Hydration™ is now being carried by Pro Hockey Life , a Canadian chain of hockey equipment stores with 20 locations in five provinces across Canada, that is a part of the Canadian Tire group of retailers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227602950/en/
On Saturday, February 22, 2025, Coach Chippy made an appearance at the Pro Hockey Life Vaughan Mills location as part of marketing initiatives for the launch of CWENCH Hydration™ at Pro Hockey Life stores (Photo: Business Wire)
Initial performance of CWENCH Hydration™ in Pro Hockey Life stores was met with substantial demand from its customer base. As a result, Pro Hockey Life submitted a re-order for additional inventory within just two weeks of receiving its first order delivery from Cizzle Brands.
Since the launch of CWENCH Hydration™ in May of 2024, Cizzle Brands has been strategically commercializing the CWENCH Hydration™ product line across North America, with a specific emphasis on hockey at the recreational, amateur, and professional levels. This strategy has resulted in an arena sponsorship with Canlan Sports , availability of the product line in other leading sporting goods retailers such as Sport Chek and Canadian Tire , as well as an endorsement deals with NHL MVP Nathan MacKinnon, Montreal Canadiens Forward Cole Caufield, and Canadian youth hockey influencer Coach Chippy , with whom Cizzle Brands collaborated to release a limited-edition "Tropical Flow" flavour of the CWENCH Hydration™ beverage. The availability of CWENCH Hydration™ at Pro Hockey Life stores further solidifies the brand's presence in the hockey community.
CWENCH Hydration™ is now available at all Pro Hockey Life locations across Canada, which are carrying a selection of flavours of the Ready-to-Drink ("RTD") TetraPak format as well as both Hydration Mix formats (10-count packets and 315-gram containers). Additionally, Pro Hockey Life is carrying CWENCH Hydration™ team and spouted water bottles and towels.
The CWENCH Hydration™ lineup at Pro Hockey Life can be viewed online at the following link: https://www.prohockeylife.com/collections/cwench
To celebrate the launch of CWENCH Hydration™ at Pro Hockey Life, Coach Chippy held a meet-and-greet event at the Pro Hockey Life Vaughan Mills location this past weekend, which attracted hundreds of attendees.
Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "We are delighted that Pro Hockey Life is carrying CWENCH Hydration™ across all of their stores, as this bolsters the brand's visibility among Canadian hockey players and fans alike. We have been very selective in choosing our retail partners during the initial launch phases of CWENCH Hydration™, and Pro Hockey Life favourably positions our products among hockey players of all ages. This placement also helps to fortify our presence in the Canadian Tire ecosystem, which is among the largest retail networks in the nation. We look forward to continuing to build up the footprint of CWENCH Hydration™ with valued retail partners such as Pro Hockey Life."
About Cizzle Brands Corporation
Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,200 stores in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.
For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/
For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com
Notice Regarding Images and Links: This press release may contain images and/or links to outside web pages, which could play an important role in providing the full context of the news update being conveyed through this press release. Some news aggregation services may remove these images and/or links at their discretion. Therefore, readers are encouraged to access SEDAR+ or the News section of the Cizzle Brands Corporation website to view this press release containing all images and/or links as originally published.
On behalf of the Board of Directors of the Company,
"John Celenza"
John Celenza, Founder, Chairman, and Chief Executive Officer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.
Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227602950/en/
For further information, please contact:
Setti Coscarella
Head of Corporate Development
investors@cizzlebrands.com
1-844-588-2088
News Provided by Business Wire via QuoteMedia